COSCIENS Biopharma Inc. (CSCIF)
| Market Cap | 6.11M -27.8% |
| Revenue (ttm) | 8.73M -3.0% |
| Net Income | 6.55M |
| EPS | 6.31 |
| Shares Out | n/a |
| PE Ratio | 0.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 367 |
| Open | 6.25 |
| Previous Close | n/a |
| Day's Range | 6.25 - 6.25 |
| 52-Week Range | 2.37 - 9.57 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important bi... [Read more]
Financial Performance
In 2025, COSCIENS Biopharma's revenue was $7.50 million, a decrease of -21.79% compared to the previous year's $9.59 million. Losses were -$10.36 million, -32.34% less than in 2024.
Financial StatementsNews
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the publication of a new corporate presentat...
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
TORONTO, ONTARIO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce, further to the press release dated Septemb...
COSCIENS ACQUIRES NUALTIS CORP.
TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the acquisition of Nualtis Corp. (“Nualtis”...
COSCIENS Biopharma Inc. Reports Q2 2026 Results
TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company”) today reported its financial and operating results for the second ...
COSCIENS Biopharma MD&A: Q2 2026
COSCIENS Biopharma filed a regulatory document on August 11, 2026 disclosing important business information.
COSCIENS Biopharma Report: Q2 2026
COSCIENS Biopharma published a report on August 11, 2026 containing material business information for investors and shareholders.
COSCIENS Biopharma Earnings release: Q2 2026
COSCIENS Biopharma released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
COSCIENS Biopharma Inc. Completes Share Capital Amendment
TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), today announced the previously announced consolidation (the “Conso...
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company'...
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
TORONTO, ONTARIO, June 18, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the results from its annual general and special meeting o...
COSCIENS Biopharma Transcript: AGM 2026
The meeting covered board elections, auditor appointment, and approval of a share consolidation and split. Management addressed a shareholder question on strategic focus, confirming ongoing cost management and prioritization of PGX. All motions were approved.
COSCIENS Biopharma Inc. Reports Q1 2026 Results
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first qua...
COSCIENS Biopharma Earnings release: Q1 2026
COSCIENS Biopharma released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
COSCIENS Biopharma Report: Q1 2026
COSCIENS Biopharma published a report on May 12, 2026 containing material business information for investors and shareholders.
COSCIENS Biopharma MD&A: Q1 2026
COSCIENS Biopharma filed a regulatory document on May 12, 2026 disclosing important business information.
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
TORONTO, ONTARIO, April 20, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced today that it has filed a Rule 13e-3 Transaction Stateme...
COSCIENS Comments on Unusual Market Activity
TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activit...
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, pla...
COSCIENS Biopharma Earnings release: Q4 2025
COSCIENS Biopharma released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
COSCIENS Biopharma Annual report: Q4 2025
COSCIENS Biopharma has published its Q4 2025 annual report on March 25, 2026.
COSCIENS Biopharma Report: Q4 2025
COSCIENS Biopharma published a report on March 25, 2026 containing material business information for investors and shareholders.
COSCIENS Biopharma MD&A: Q4 2025
COSCIENS Biopharma filed a regulatory document on March 25, 2026 disclosing important business information.
COSCIENS Provides Strategic Update
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to ...
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagn...
COSCIENS Biopharma Inc. Announces Leadership Change
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmace...